GlassScriptPhysician profile
Rubyanne E Deveras
NPI 1306844360
$11,334.45
in general payments reported to CMS, 2019-2025
43 companies · $2,324 in 2025
The $2,324 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $474 · 2021: $1,082 · 2022: $972 · 2023: $1,503 · 2024: $2,102 · 2025: $2,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,883 · Education: $46.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,882.88 |
| Education | $46.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,749.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,386.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $869.92 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $644.36 | 2020-2025 | Opdivo |
| Daiichi Sankyo INC. | $579.66 | 2021-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $489.95 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $464.09 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Lilly USA, LLC | $453.65 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $321.82 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Penumbra, INC. | $302.55 | 2025 | Indigo System |
| Pfizer INC. | $284.66 | 2023-2025 | |
| Amgen INC. | $279.38 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Janssen Biotech, INC. | $275.98 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $273.47 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Genentech USA, INC. | $269.45 | 2019-2025 | Phesgo, Perjeta, Kadcyla |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $254.86 | 2021-2025 | Trodelvy |
| Novo Nordisk INC | $204.84 | 2019-2021 | |
| Celgene Corporation | $193.44 | 2019-2025 | Reblozyl |
| Eisai INC. | $185.07 | 2019-2024 | |
| Caris Mpi, INC. | $181.79 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $173.44 | 2024-2025 | Vyloy, Xtandi |
| Stemline Therapeutics INC. | $172.07 | 2024 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $164.33 | 2019-2024 | |
| Adc Therapeutics America, INC. | $157.31 | 2024-2025 | |
| Exelixis INC. | $155.62 | 2019-2024 | Cabometyx |
| Genzyme Corporation | $143.03 | 2021-2025 | |
| Taiho Oncology, INC. | $130.25 | 2021-2025 | |
| Puma Biotechnology, INC. | $115.06 | 2020-2025 | |
| Abbvie INC. | $84.93 | 2024 | |
| Foundation Medicine, INC. | $57.43 | 2021 | |
| Csl Behring | $51.67 | 2022-2023 | Idelvion, Afstyla |
| Emd Serono, INC. | $33.39 | 2019-2025 | |
| Tempus Ai, INC | $32.70 | 2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $26.07 | 2024 | Libtayo |
| Glaxosmithkline, LLC. | $24.99 | 2019 | |
| Dova Pharmaceuticals | $22.03 | 2020 | |
| Geron Corporation | $21.09 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Beone Medicines USA, INC. | $19.61 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $17.66 | 2023 | Vonjo |
| Sanofi-Aventis U.S. LLC | $17.23 | 2021 | |
| G1 Therapeutics, INC. | $15.76 | 2022 | |
| Sun Pharmaceutical Industries INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubyanne Deveras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.